These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32770654)

  • 21. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
    Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
    Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.
    Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2021; 12():765097. PubMed ID: 34777381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in CAR T Therapy for Hematologic Malignancies.
    Freyer CW; Porter DL
    Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
    Taraseviciute A; Tkachev V; Ponce R; Turtle CJ; Snyder JM; Liggitt HD; Myerson D; Gonzalez-Cuyar L; Baldessari A; English C; Yu A; Zheng H; Furlan SN; Hunt DJ; Hoglund V; Finney O; Brakke H; Blazar BR; Berger C; Riddell SR; Gardner R; Kean LS; Jensen MC
    Cancer Discov; 2018 Jun; 8(6):750-763. PubMed ID: 29563103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
    Kersten MJ; van Ettekoven CN; Heijink DM
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.
    Lapidus AH; Anderson MA; Harrison SJ; Dickinson M; Kalincik T; Lasocki A
    Leuk Lymphoma; 2022 Oct; 63(10):2364-2374. PubMed ID: 35570737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission.
    Bai Z; Feng B; McClory SE; de Oliveira BC; Diorio C; Gregoire C; Tao B; Yang L; Zhao Z; Peng L; Sferruzza G; Zhou L; Zhou X; Kerr J; Baysoy A; Su G; Yang M; Camara PG; Chen S; Tang L; June CH; Melenhorst JJ; Grupp SA; Fan R
    Nature; 2024 Oct; 634(8034):702-711. PubMed ID: 39322664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
    Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
    Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.
    Shalabi H; Gust J; Taraseviciute A; Wolters PL; Leahy AB; Sandi C; Laetsch TW; Wiener L; Gardner RA; Nussenblatt V; Hill JA; Curran KJ; Olson TS; Annesley C; Wang HW; Khan J; Pasquini MC; Duncan CN; Grupp SA; Pulsipher MA; Shah NN
    Nat Rev Clin Oncol; 2021 Jun; 18(6):363-378. PubMed ID: 33495553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Not Available].
    Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.